LEIPZIG, Germany: The US pharmaceutical company Novalar has launched their latest premier dental product OraVerse at the Chicago Midwinter Meeting held in Chicago in February. The product is the first local anaesthesia reversal agent that accelerates the return to normal sensation and function for patients who wish to avoid the lingering soft tissue anaesthesia following routine dental procedures in which a local anaesthetic containing a vasoconstrictor was used.
OraVerse was approved by the US Food and Drug Administration last year as safe and effective for adults and children six years and older and weighing 33 lbs. In two randomised, double-blinded, controlled Phase 3 studies, the agent reduced the median time to recovery of normal sensation in the lower and upper lip to approximately half the time compared to the control. Both studies were conducted on over 400 patients in 18 centres across the US.
“How to address soft tissue numbness is one of the most commonly asked questions in dentistry,” Dr Stanley Malamed, Professor of Anaesthesia & Medicine at the University of Southern California School of Dentistry, said. “OraVerse is the first solution of its kind that dentists can use to finally answer this question. It will provide dentists with a convenient alternative for completing routine dental procedures that allows patients to comfortably return to their daily routine”.
The active ingredient in OraVerse is phentolamine mesylate, a drug already used in other medical applications, such as the prevention or control of hypertensive episodes that may occur in patients with pheochromocytoma because of stress or manipulation during preoperative preparation and surgical excision. According to the company, OraVerse will come in a standard dental cartridge that can be easily injected utilising the same injection site and an identical technique to that of a local anaesthetic. It is used in a 1:1 ratio to local anaesthetic and has been tested in doses of 0.5, 1 and 2 cartridges.
NEW YORK, N.Y., USA: Regular use of fluoride toothpaste containing triclosan, an antibacterial agent, and a copolymer, which helps prevent the triclosan ...
Carrying on the conversation from the first part on the ongoing fight for improved safety in anaesthesia in dentistry, Dental Tribune International again ...
Last April, Dental Tribune International first spoke with Drs Rita Agarwal and James Tom, paediatric anaesthesiologist and dentist anaesthesiologist, ...
NEW YORK, USA/LEIPZIG, Germany: Novalar Pharmaceuticals has announced to have chosen Sanofi-Aventis Deutschland as exclusive distributor of their OraVerse ...
LIVINGSTON, N.J., & WOODINVILLE, Wash., USA: Aseptico has been announced as new distributor for Milestone Scientific's Single Tooth Anesthesia (STA) in ...
PROVO, Utah, USA: Curve Dental, a provider of cloud-based dental solutions, has announced the release of Curve GRO, the company’s next-generation patient ...
NEW YORK, N.Y., USA: In some situations, general anesthesia is the best option for pediatric dental patients undergoing treatment. However, the cost of such...
NEW YORK, U.S.: Weave, a Utah-based startup company and one of the fastest-growing companies in technology, has taken the opportunity at the 2019 Greater ...
DALLAS, Texas, USA: Fotona, based in the U.S. and Europe, will launch its new ST PRO Lightwalker dental laser at the upcoming 151st Midwinter Meeting of the...
Finnigan Enterprises announced the launch of Oxford Scientific Dental Products at the American Dental Association’s annual meeting, held recently in ...
Live webinar
Tue. 6 August 2024
6:00 PM EST (New York)
Live webinar
Tue. 6 August 2024
8:00 PM EST (New York)
Dr. Cameron Shahbazian DMD MBA
Live webinar
Tue. 13 August 2024
7:00 PM EST (New York)
Live webinar
Wed. 14 August 2024
12:30 PM EST (New York)
Live webinar
Wed. 21 August 2024
9:00 AM EST (New York)
Dr. Jim Lai DMD, MSc(Perio), EdD, FRCD(C)
Live webinar
Thu. 22 August 2024
4:00 PM EST (New York)
Live webinar
Wed. 28 August 2024
8:00 PM EST (New York)
To post a reply please login or register